In conclusion, we were able to demonstrate that the biomarker-based GALAD score clearly outperforms the biomarkers AFP, DCP and AFP-L3 used individually for early-stage HCC detection in a Caucasian cohort of chronic hepatitis B or C patients. This evidence concerns the gene AFP and hepatocellular carcinoma.